Hongming Chen's Insider Trades & SAST Disclosures
Hongming Chen's most recent trade in Kala Pharmaceuticals Inc was a trade of 21,051 Common Stock done at an average price of $1.8 . Disclosure was reported to the exchange on Oct. 26, 2021.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Hongming Chen.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kala Pharmaceuticals Inc | Hongming Chen | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 1.82 per share. | 26 Oct 2021 | 21,051 | 204,515 (0%) | 0% | 1.8 | 38,313 | Common Stock |
| Kala Pharmaceuticals Inc | Hongming Chen | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 1.80 per share. | 26 Oct 2021 | 9,449 | 225,566 (0%) | 0% | 1.8 | 17,008 | Common Stock |
| Kala Pharmaceuticals Inc | Hongming Chen | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 5.56 per share. | 29 Jun 2021 | 5,548 | 235,015 (0%) | 0% | 5.6 | 30,847 | Common Stock |
| Kala Pharmaceuticals Inc | Hongming Chen | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 5.77 per share. | 28 Jun 2021 | 2,452 | 240,563 (0%) | 0% | 5.8 | 14,148 | Common Stock |
| Kala Pharmaceuticals Inc | Hongming Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 9,500 | 53,736 | - | - | Stock Option (right to buy | |
| Kala Pharmaceuticals Inc | Hongming Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.30 per share. | 01 Mar 2021 | 9,500 | 243,015 (0%) | 0% | 2.3 | 21,850 | Common Stock |
| Kala Pharmaceuticals Inc | Hongming Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2021 | 47,000 | 63,236 | - | - | Stock Option (right to buy) | |
| Kala Pharmaceuticals Inc | Hongming Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.30 per share. | 25 Feb 2021 | 47,000 | 233,515 (0%) | 0% | 2.3 | 108,100 | Common Stock |
| Kala Pharmaceuticals Inc | Hongming Chen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 90,667 | 90,667 | - | - | Stock Option (right to buy) | |
| Kala Pharmaceuticals Inc | Hongming Chen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 22,666 | 186,515 (0%) | 0% | 0 | Common Stock | |
| Kala Pharmaceuticals Inc | Hongming Chen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2020 | 61,000 | 163,849 (0%) | 0% | 0 | Common Stock | |
| Kala Pharmaceuticals Inc | Hongming Chen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 16,000 | 102,849 (0%) | 0% | 0 | Comman Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges